Format

Send to

Choose Destination
Blood Cancer J. 2017 Mar 10;7(3):e542. doi: 10.1038/bcj.2017.21.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.

Author information

1
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
3
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4
Division of General Medical Sciences, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center